Heart failure with reduced ejection fraction is a clinical syndrome of dysp­ nea, exercise intolerance and/or edema resulting from an impairment of ejec­ tion of blood, usually documented by a left ventricular ejection fraction of 40% or less on echocardiography.1,2 Cor on­ ary artery disease is a major cause; therefore, stress testing or, in the pres­ ence of angina, coronary angiography shoul...

Nearly half of patients with symptoms of heart failure are found to have a normal left ventricular (LV) ejection fraction. This has variously been labelled as diastolic heart failure, heart failure with preserved LV function or heart failure with a normal ejection fraction (HFNEF). As recent studies have shown that systolic function is not entirely normal in these patients, HFNEF is the preferr...

The response of right ventricular ejection fraction (RVEF) during exercise and its relationship to the location and extent of coronary artery disease are not fully understood. We have recently developed and validated a new method for scintigraphic evaluation of RVEF using rapid multiple-gated equilibrium scintigraphy and multiple right ventricular regions of interest. The technique has been app...

Changes in left ventricular (LV) volumes and ejection fraction between rest and maximal supine exercise were evaluated in 11 patients who had had four epicardial markers placed during coronary artery surgery. After calibrating marker distances with respect to volume (r = 0.92--0.99) over one cardiac cycle for each patient, regression equations were used to compute LV volume from marker measurem...

Quantitative assessment of left ventricular function was performed by single plane cineangiography in I3 patients with ischaemic heart disease without clinical heart failure. As compared with normal controls, 7 of I3 patients had a reduced ejection fraction and 'normalized' ejection rate, suggesting impaired left ventricular function. These patients could not be differentiated clinically in any...

Abstract Background Despite advances in treatment of heart failure with preserved ejection fraction (HFpEF) its management remains challenging. SGLT2 inhibitors benefits across the full range fraction, and sacubitril/valsartan up to lower end EF <57% implies that some patients HFpEF pathophysiological mechanisms HFrEF might co-exist, subset benefit from proven HFrEF, particularly those d...